<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesús Rojas-Jaimes</style></author><author><style face="normal" font="default" size="100%">Marco Mesía-Guevara</style></author><author><style face="normal" font="default" size="100%">Alexander Murillo-Zenozain</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Butionin-Sulfaximine and Fluphenazine as Trypanothione Inhibitory Drugs on Promastigotes and Axenic Amastigotes of Leishmania Peruviana and Leishmania Braziliensis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Axenic Amastigote</style></keyword><keyword><style  face="normal" font="default" size="100%">Butionin-Sulfaximine</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluphenazine</style></keyword><keyword><style  face="normal" font="default" size="100%">Leishmania</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">82-85</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Leishmaniasis is a disease caused by the &lt;em&gt;Leishmania parasite&lt;/em&gt;, which is difficult to diagnose, causes disfigurement and is difficult to treat. Objectives: To determine the effect of Butionin-Sulfaximine (BSO) and Fluphenazine on trypomastigotes and axenic amastigotes of &lt;em&gt;Leishmania peruviana&lt;/em&gt; and &lt;em&gt;Leishmania braziliensis&lt;/em&gt;. &lt;strong&gt;Methods:&lt;/strong&gt; A study was performed with Butionin-Sulfaximine (BSO), Fluphenazine, and Glucantime (positive control,) utilizing respective concentrations of 41.7 mg/ml, 4.17 mg/ml, and 50 mg/ml for twenty-four hours on axenic amastigotes. &lt;strong&gt;Results:&lt;/strong&gt; A significant difference (*P &amp;lt; 0.05) was found between the negative control group, Fluphenazine, and BSO within both the axenic amastigotes of L. peruviana (5.5 X 10&lt;sup&gt;5&lt;/sup&gt; / ml for the negative control, 0.15 X 10&lt;sup&gt;5&lt;/sup&gt; / ml for Fluphenazine, and 0.7 X 10&lt;sup&gt;5&lt;/sup&gt; / ml for BSO) and &lt;em&gt;L. braziliensis &lt;/em&gt;(6.9 X 10&lt;sup&gt;5&lt;/sup&gt;/ml for the negative control, 0.18 X 10&lt;sup&gt;5&lt;/sup&gt;/ml for Fluphenazine, and 0.22 X 10&lt;sup&gt;5&lt;/sup&gt;/ml for BSO). Another significant difference (*P &amp;lt; 0.05) was found in the promastigotes of L. peruviana (5.9 X 10&lt;sup&gt;5&lt;/sup&gt; / ml for the negative control, 0.66 X 10&lt;sup&gt;5 &lt;/sup&gt;/ ml for Fluphenazine, and 3.1 X 10&lt;sup&gt;5&lt;/sup&gt; / ml for BSO) and L. braziliensis (8.7 X 10&lt;sup&gt;5&lt;/sup&gt;/ml for the negative control and 5.68 X 10&lt;sup&gt;5&lt;/sup&gt;/ml for Fluphenazine). &lt;strong&gt;Conclusions: &lt;/strong&gt;From this, we conclude Fluphenazine and BSO present promising antiparasitic effects against axenic amastigotes of L. peruviana and L. braziliensis in both pharmacological tests of the in vivo model and their potential future use.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">82</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Jesús Rojas-Jaimes&lt;sup&gt;1,2,*&lt;/sup&gt;, Marco Mesia-Guevara&lt;sup&gt;1&lt;/sup&gt;, Alexander Murillo- Zenozain&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;College of Human Medicine, Universidad Científica del Sur, Lima, PERÚ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Health Sciences Faculty, Universidad Privada del Norte, Lima, PERÚ.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesús Rojas-Jaimes</style></author><author><style face="normal" font="default" size="100%">Luis Castañeda Pelaez</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Generation of Multinucleated Giant Cells due to Leishmania (V.) braziliensis Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Leishmania (V.) braziliensis</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophage</style></keyword><keyword><style  face="normal" font="default" size="100%">Multinucleated Giant Cells</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">905-909</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Multinucleated giant cells were first described by Langhans(MGCs), these MGCs have a role in innate immunity that includes extracellular matrix remodeling associated with granuloma formation; another function of them is to participate in the removal of cellular debris in apoptosis during certain infections. &lt;strong&gt;Objective: &lt;/strong&gt;Generate multinucleated giant cells due to &lt;em&gt;Leishmania &lt;/em&gt;(V.) braziliensis infection. &lt;strong&gt;Methods:&lt;/strong&gt; For infection macrophage/parasite ratio of 1 to 10 using the RAW 264.7-line (5 x10&lt;sup&gt;5&lt;/sup&gt;/mL) and &lt;em&gt;Leishmania &lt;/em&gt;(V.) &lt;em&gt;braziliensis &lt;/em&gt;metacyclic promastigotes (50 x105/mL) was a strain maintained in culture Schneider liquid medium, supplemented with 20% fetal bovine serum and 10 000 U/10 mg/mL penicillin streptomycin at pH 7 and 25 °C in the laboratory. Incubation was continued for 4 days, and microscopic observation at 1000X was performed at 24 hours and 96 hours, respectively. &lt;strong&gt;Results: &lt;/strong&gt;In our study an MGC conversion was observed at 96 hours (50% ± 28.2). &lt;strong&gt;Conclusions:&lt;/strong&gt; In vitro MGC model could be used to study the physiopathology of MGC generation by &lt;em&gt;Leishmania &lt;/em&gt;(V.) &lt;em&gt;braziliensis &lt;/em&gt;infection.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">905</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Jesús Rojas-Jaimes&lt;sup&gt;1,2,*&lt;/sup&gt;, Luis Castañeda Pelaez&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Facultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, PERÚ.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Escuela de Medicina Humana, Universidad Científica del Sur, Lima, PERÚ.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesús Rojas-Jaimes</style></author><author><style face="normal" font="default" size="100%">Marco Mesía-Guevara</style></author><author><style face="normal" font="default" size="100%">Maria Rojas-Puell</style></author><author><style face="normal" font="default" size="100%">Luis Castañeda- Pelaez</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiparasitic effect of Psidium guajava on promastigotes and axenic amastigotes of Leishmania</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amastigote</style></keyword><keyword><style  face="normal" font="default" size="100%">Leishmania</style></keyword><keyword><style  face="normal" font="default" size="100%">Promastigote</style></keyword><keyword><style  face="normal" font="default" size="100%">Psidium guajava</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">973-977</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Leishmaniasis is a stigmatic and mutilating disease due to pathogenic species of the genus Leishmania which, depending on the species and the individual's immune status, may vary clinically from a cutaneous, mucosal, and visceral form, and for which there is no suitable treatment without significant side effects.&lt;strong&gt; Objectives: &lt;/strong&gt;To measure the effect of ethanolic and aqueous extracts of&lt;em&gt; Psidium guajava&lt;/em&gt; against axenic promastigotes and amastigotes of &lt;em&gt;Leishmania spp.&lt;/em&gt; Methods: The method of [3- (3,4 -dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] was used to study the antiparasitic effects of ethanolic (100mg/mL) and aqueous (100mg/mL) extracts of &lt;em&gt;Psidium guajava&lt;/em&gt; on axenic amastigotes cultures (8.1 x103 parasite/mL) and promastigotes (12 x 104 parasite/mL) obtained from a patient with cutaneous&amp;nbsp;leishmaniasis, and the percentage of parasite death was evaluated in comparison with Glucantime (300mg/mL) and untreated parasite cultures. &lt;strong&gt;Results: &lt;/strong&gt;Regarding parasite death in promastigotes, the ethanolic and aqueous extracts had a percentage of 22.58% and -45.16%, respectively, with no significant difference between treatments (N=3) (p= 0.058). In contrast, the ethanolic and aqueous extracts had an antiparasitic percentage of 91.67% and -70.83%, respectively, with a significant difference between treatments (N=3) (p&amp;lt;0.05).&lt;strong&gt; Conclusions: &lt;/strong&gt;Our study showed high and significant effectiveness in parasite death (91.67%) of &lt;em&gt;Leishmania&lt;/em&gt; axenic amastigotes of the ethanolic extract (100mg/mL) of &lt;em&gt;Psidium guajava,&lt;/em&gt; being this result promising and the basis for in vivo studies, using the ethanolic extraction of P. guajava&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><section><style face="normal" font="default" size="100%">973-977</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Jesús Rojas-Jaimes&lt;sup&gt;1,2,*&lt;/sup&gt;, Marco Mesía-Guevara&lt;sup&gt;1&lt;/sup&gt;, Maria Rojas- Puell&lt;sup&gt;1&lt;/sup&gt;, Luis Castañeda- Pelaez&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, PERU.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Facultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, PERU.&lt;/p&gt;
</style></auth-address></record></records></xml>